Search - tctmd.com

Displaying 61 - 80 of 807

Sort: Relevancy | Date

News Daily News

At 3 Years Post-TAVR, Valve Performance Holds Steady and Most Mortality Is Noncardiac: FRANCE 2 Registry

Caitlin E. Cox

October 04, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2016

Shelley Wood

September 30, 2016

News Daily News

TCTMD’s Top 10 Most Popular Stories for September 2016

Shelley Wood

September 30, 2016

News Daily News

Post-TAVR Cognition Improves in Some Patients and Declines in Others, With Few Signposts to Guide the Way

Shelley Wood

September 29, 2016

News Daily News

New ‘Rapid Recommendations’ Tackle TAVR in Patients at Low-to-Intermediate Risk

Todd Neale

September 29, 2016

TAVR vs SAVR: Limitations and Risks Debated as Transcatheter Therapies Move Into Younger and Lower-Risk Patients

Shelley Wood

September 20, 2016

News Daily News

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

Michael O'Riordan

September 20, 2016

News Conference News PCR London Valves 2016

Innovation Overload? Too Many Novel Ideas May Be Holding Back Progress in Transcatheter Mitral Valve Technologies

Shelley Wood

September 19, 2016

News Industry News

Edwards Sapien 3 Transcatheter Heart Valve Receives Expanded Indication In Europe

September 19, 2016

News Industry News

Boston Scientific Receives CE Mark For LOTUS Edge™ Valve System

September 19, 2016

News Daily News

Elderly Asymptomatic Patients With Severe AS Are Often Treated Too Late

L.A. McKeown

September 16, 2016

News Daily News

Stroke Risk With TAVR: In-Depth Review of PARTNER and CoreValve Data Reveals Opportunities and Unknowns

Shelley Wood

September 13, 2016

News Daily News

TAVR as an Option for Intermediate-Risk Patients: Physicians Respond

Yael L. Maxwell

August 24, 2016

News Daily News

Survival Better, No ‘Risk Creep’ for TAVR vs Surgery in Lower-Risk Patients

L.A. McKeown

August 24, 2016

News Daily News

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

Yael L. Maxwell

August 18, 2016

News Industry News

EDWARDS INTUITY Elite Rapid Deployment Valve Receives FDA Approval

August 15, 2016

News Daily News

CLEAN-TAVI:TAVR 脑栓塞预防结果公布

Yael L. Maxwell

August 15, 2016

News Daily News

CLEAN-TAVI: Se Publican los Resultados de Protección Embólica Cerebral en TAVR

Yael L. Maxwell

August 15, 2016

Presentation

CLEAN-TAVI: Effect of a Cerebral Protection Device on Brain Lesions Following TAVR in Patients With Severe Aortic Stenosis

Presenter: S. Haussing

August 11, 2016

Presentation

Predictors of Early Cerebrovascular Events in Patients With Aortic Stenosis Undergoing TAVR

Presenter: Vincent Auffret

August 10, 2016

Advertisement

At 3 Years Post-TAVR, Valve Performance Holds Steady and Most Mortality Is Noncardiac: FRANCE 2 Registry

TCTMD’s Top 10 Most Popular Stories for September 2016

TCTMD’s Top 10 Most Popular Stories for September 2016

Post-TAVR Cognition Improves in Some Patients and Declines in Others, With Few Signposts to Guide the Way

New ‘Rapid Recommendations’ Tackle TAVR in Patients at Low-to-Intermediate Risk

TAVR vs SAVR: Limitations and Risks Debated as Transcatheter Therapies Move Into Younger and Lower-Risk Patients

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

Innovation Overload? Too Many Novel Ideas May Be Holding Back Progress in Transcatheter Mitral Valve Technologies

Edwards Sapien 3 Transcatheter Heart Valve Receives Expanded Indication In Europe

Boston Scientific Receives CE Mark For LOTUS Edge™ Valve System

Elderly Asymptomatic Patients With Severe AS Are Often Treated Too Late

Stroke Risk With TAVR: In-Depth Review of PARTNER and CoreValve Data Reveals Opportunities and Unknowns

TAVR as an Option for Intermediate-Risk Patients: Physicians Respond

Survival Better, No ‘Risk Creep’ for TAVR vs Surgery in Lower-Risk Patients

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

EDWARDS INTUITY Elite Rapid Deployment Valve Receives FDA Approval

CLEAN-TAVI:TAVR 脑栓塞预防结果公布

CLEAN-TAVI: Se Publican los Resultados de Protección Embólica Cerebral en TAVR

CLEAN-TAVI: Effect of a Cerebral Protection Device on Brain Lesions Following TAVR in Patients With Severe Aortic Stenosis

Predictors of Early Cerebrovascular Events in Patients With Aortic Stenosis Undergoing TAVR

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content